Autoimmune nature of influenza atherogenicity

Annals of the New York Academy of Sciences

Volumn 1050, Issue , 2005, Pages 410-416

  Gurevich, Victor S ^a   Pleskov, Vladimir M ^b   Levaya, Margarita V ^a  

^a NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^b Laboratory of Pathomorphology   (Russian Federation)

Author keywords

Atherosclerosis; Autoantibodies to oxidized LDL; Autoimmunity; Influenza; Molecular mimicry

Indexed keywords

AUTOANTIBODY; FIBRIC ACID DERIVATIVE; INFLUENZA VACCINE; OXIDIZED LOW DENSITY LIPOPROTEIN; STATINE DERIVATIVE;

ATHEROGENESIS; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; EPIDEMIC; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; RHABDOMYOLYSIS;

EID: 23744493424     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1313.092     Document Type: Conference Paper

References (40)

1. TILLETT, H.E., J.W. SMITH & C.D. GOOCH. 1983. Excess deaths attributable to influenza in England and Wales: age at death and certified cause. Int. J. Epidemiol. 12: 344-352.
2. BONDARENKO, S.S. & F.A. TUMANOV. 1993. The effect of influenza and para-influenza on the course of ischemic heart disease. Ter. Arkh. 64: 81-83.
3. VULLERS, R., B. BULTMANN, H. FISCHER et al. 1980. Influenza A virus infection, a precipitating factor for the major heart attack. Muench. Med. Wochenschr. 122: 1415-1417.
4. FABRICANT, C.G., J. FABRICANT, M.M. LITRENTA et al. 1978. Virus-induced atherosclerosis. J. Exp. Med. 148: 335-340.
5. JARA, L.J., G. MEDINA, O. VERA-LASTRA et al. 2003. Atherosclerosis and antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 25: 79-88.
6. BROWN, M.S. & J.L. GOLDSTEIN. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52: 223-261.
7. KODAMA, T., P. REDDY, C. KISHIMOTO et al. 1988. Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 85: 9238-9242.
8. KRIEGER, M. & J. HERZ. 1994. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu. Rev. Biochem. 63: 601-637.
9. STEINBERG, D. & J.L. WITZTUM. 1990. Lipoproteins and atherogenesis: current concepts. JAMA 264: 3047-3052.
10. SALONEN, J.T., S. YLA-HERTTUALA, R. YAMAMOTO et al. 1992. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 339: 883-887.
11. NICOLETTI, A., S. KAVERI, G. CALIGIURY et al. 1998. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J. Clin. Invest. 102: 910-918.
12. VAN DER WAL, A.C., P. DAS, D.B. VAN DE BERG et al. 1989. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab. Invest. 61: 166-170.
13. + T cells aggravates atherosclerosis in immunodeficient apoprotein E knockout mice. Circulation 102: 2919-2922.
14. GEORGE, J. & Y.S. SHOENFELD. 1995. Atherosclerosis as autoimmune disease. Harefuah 129: 257-259.
15. 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 39: 1466-1474.
16. FROSTEGARD, J. 2002. Autoimmunity, oxidized LDL, and cardiovascular disease. Autoimmun. Rev. 4: 233-237.
17. AZAMBUJA, M.I. & B.B. DUNCAN. 2002. Similarities in mortality patterns from influenza in the first half of the 20th century and the rise and fall of ischemic heart disease in the United States: a new hypothesis concerning the coronary heart disease epidemic. Cad. Saude Pub. 18: 557-577.
18. AZAMBUJA, M.I. 2004. Spanish flu and early 20th-century expansion of a coronary heart disease-prone subpopulation. Tex. Heart Inst. J. 31: 14-21.
19. KEATINGE, W.R. 2002. Winter mortality and its causes. Int. J. Circumpolar. Health 61: 292-299.
20. HAIDER, A.W., M.G. LARSON, CJ. O'DONNELL et al. 1999. The association of chronic cough with the risk of myocardial infarction: the Framingham Heart Study. Am. J. Med. 106: 279-284.
21. HUGHES, S. 2003. Novel cardiovascular risk factors. J. Cardiovasc. Nurs. 18: 131-138.
22. MADJID, M., I. ABOSHADY, I. AWAN et al. 2004. Influenza and cardiovascular disease: is there a causal relationship? Tex. Heart Inst. J. 31: 4-13
23. HAK, E., T.J. VERHEIJ, G.A. VAN ESSEN et al. 2001. Prognostic factors for influenza-associated hospitalization and death during an epidemic. Epidemiol. Infect. 126: 261-268.
24. DVORAKOVA, A. & R. POLEDNE. 2004. Influenza-a trigger for acute myocardial infarction. Atherosclerosis 172: 391-392.
25. GUREVICH, V.S., V.M. PLESKOV, M.V. LEVAYA et al. 2002. Influenza virus infection in progressing atherosclerosis. Kardiologia 42: 21-24.
26. ENGBLOM, E., T.O. EKFORS, O.K. MEURMAN et al. 1983. Fatal influenza A myocarditis with isolation of virus from the myocardium. Acta Med. Scand. 213: 75-78.
27. CATON, A., D.M. CERASOLI & F.F. SHIH. 1998. Immune recognition of influenza hemagglutinin as a viral and a neo-self-antigen. Immunol. Res. 17: 23-32.
28. REED, A.J., M.P. RILEY & A.J. CATON. 2000. Virus-induced maturation and activation of autoreactive memory B cells. J. Exp. Med. 192: 1763-1774.
29. VAN LENTEN, B.J., A.C. WAGNER, G.M. ANANTHARAMAIAH et al. 2002. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106: 1127-1132.
30. BOUWMAN, J.J., F.L. VISSEREN, M.C. BOSCH et al. 2002. Procoagulant and inflammatory response of virus-infected monocytes. Eur. J. Clin. Invest. 32: 759-766.
31. GUREVICH, V., V. PLESKOV & S. URAZGILDEEVA. 2004. The role of immune response to influenza virus in progression of atherosclerosis [abstract]. Clin. Exp. Rheumatol. 22: 13.
32. KLIMOV, A.N., V.S. GUREVICH, A.A. NIKIFOROVA et al. 1993. Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis 100: 13-18.
33. NAVAB, M., J.A. BERLINER, G. SUBBANAGOUNDER et al. 2001. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arter. Thromb. Vascul. Biol. 21:481-488.
34. NAGHAVI, M., Z. BARLAS & S. SIADATY. 2000. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 102: 3039-3045.
35. GURFINKEL, E. & R.L. DE LA FUENTE. 2004. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) registry. Tex. Heart Inst. J. 31: 28-32.
36. JACKSON, L.A., O. Yu & S.R. HECKBERT. 2002. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am. J. Epidemiol. 156: 634-640.
37. RITTER, O., A. BONZ, J. STROTMANN et al. 2003. Myocardial infarction after influenza vaccination. Z. Kardiol. 92: 962-965.
38. GEIER, M.R., D.A. GEIER & A.C. ZAHALSKY. 2003. Influenza vaccination and Guillain Barré syndrome small star, filled. Clin. Immunol. 107: 116-121.
39. PLOTKIN, E., J. BERNHEIM, S. BEN-CHETRIT et al. 2000. Influenza vaccine-a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibrate. Nephrol. Dial. Transplant. 15: 740-741.
40. CHAZAN, B., R. WEISS & H. TABENKIN. 2002. Influenza vaccine does not produce myopathy in patients taking statins. J. Fam. Pract. 51: 986-988.